|
Vertex Pharmaceuticals Inc (VRTX) |
|
|
|
VRTX's Revenue Growth by Quarter and Year
Vertex Pharmaceuticals Inc's Revenue results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
|
VRTX Revenue (in millions $) |
FY 2023 |
FY 2022 |
FY 2021 |
FY 2020 |
IV Quarter |
December |
2,517.70
|
2,302.70
|
2,072.56
|
1,627.82
|
III Quarter |
September |
2,483.50
|
2,334.30
|
1,984.16
|
1,538.27
|
II Quarter |
June |
2,493.20
|
2,196.20
|
1,793.37
|
1,524.49
|
I Quarter |
March |
2,374.80
|
2,097.50
|
1,724.31
|
1,515.11
|
FY |
|
9,869.20
|
8,930.70
|
7,574.40
|
6,205.69
|
VRTX Revenue fourth quarter 2023 Y/Y Growth Comment |
Vertex Pharmaceuticals Inc reported Revenue growth of 9.34% year on year in the fourth quarter 2023, to $ 2,517.70 millions, this is lower than Vertex Pharmaceuticals Inc's recent average Revenue improvement of 31.61%.
Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 15 other companies have achieved higher Revenue growth. While Vertex Pharmaceuticals Inc' s Revenue increase of 9.34% ranks overall at the positon no. 399 in the fourth quarter 2023.
|
VRTX Revenue ( Y/Y Growth %) |
2023
|
2022 |
2021 |
2020 |
IV Quarter |
December |
9.34 % |
11.1 % |
27.32 % |
15.18 % |
III Quarter |
September |
6.39 % |
17.65 % |
28.99 % |
61.95 % |
II Quarter |
June |
13.52 % |
22.46 % |
17.64 % |
61.96 % |
I Quarter |
March |
13.22 % |
21.64 % |
13.81 % |
76.5 % |
FY |
|
10.51 % |
17.91 % |
22.06 % |
49.07 % |
VRTX Revenue (Quarter on Quarter Growth %) |
2023
|
2022 |
2021 |
2020 |
IV Quarter |
December |
1.38 % |
-1.35 % |
4.46 % |
5.82 % |
III Quarter |
September |
-0.39 % |
6.29 % |
10.64 % |
0.9 % |
II Quarter |
June |
4.99 % |
4.71 % |
4.01 % |
0.62 % |
I Quarter |
March |
3.13 % |
1.2 % |
5.93 % |
7.21 % |
FY (Year on Year) |
|
10.51 % |
17.91 % |
22.06 % |
49.07 % |
Revenue Y/Y Growth Statistics |
High |
Average |
Low |
147.95 % |
31.61 % |
-67.04 % |
(June 30. 2016) |
|
(Sep. 30, 2014) |
|
Revenue Y/Y Growth Statistics |
High |
Average |
Low |
147.95 % |
31.61 % |
-67.04 % |
(June 30. 2016) |
|
(Sep. 30, 2014) |
|
Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023 |
Vertex Pharmaceuticals Inc's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics |
High |
Average |
Low |
86.55 % |
5.76 % |
-78.5 % |
(Sep 30 2015) |
|
|
VRTX's IV. Quarter Q/Q Revenue Comment |
Vertex Pharmaceuticals Inc achieved in the IV. Quarter 2023 below company average Revenue growth of 1.38% quarter on quarter, to $ 2,517.70 millions.
Even if the IV. Quarter 2023 results were beneath the regular , this was still promising news, as the IV. Quarter expension, transcends the -1.35% growth in the IV. Quarter a year ago
Within Major Pharmaceutical Preparations industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Vertex Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 341. |
|
|
Revenue Q/Q Growth Statistics |
High |
Average |
Low |
86.55 % |
5.76 % |
-78.5 % |
(Sep 30 2015) |
|
|
VRTX's IV. Quarter Q/Q Revenue Comment |
Vertex Pharmaceuticals Inc achieved in the IV. Quarter 2023 below company average Revenue growth of 1.38% quarter on quarter, to $ 2,517.70 millions.
IV. Quarter 2023 Vertex Pharmaceuticals Inc's results seem to be contradictory, albeit below the ordinary, yet it shows a quite improvement relative to the -1.35% in the IV. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Vertex Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 341. |
|
Vertex Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending (Dec 31 2023) |
12 Months Ending (Sep 30 2023) |
12 Months Ending (Jun 30 2023) |
12 Months Ending (Mar 31 2023) |
12 Months Ending (Dec 31 2022) |
Cumulative Revenue 12 Months Ending |
$ 9,869.20 |
$ 9,654.20 |
$ 9,505.00 |
$ 9,208.00 |
$ 8,930.70 |
Y / Y Revenue Growth (TTM) |
10.51 % |
10.96 % |
13.83 % |
15.86 % |
17.91 % |
Year on Year Revenue Growth Overall
Ranking |
# 116 |
# 345 |
# 173 |
# 322 |
# 681 |
Seqeuential Revenue Change (TTM) |
2.23 % |
1.57 % |
3.23 % |
3.11 % |
2.65 % |
Seq. Revenue Growth (TTM) Overall
Ranking |
# 399 |
# 1448 |
# 564 |
# 2131 |
# 2136 |
Cumulative Revenue growth
Comment |
With the quarterly Revenue reported in the Dec 31 2023 period, Vertex Pharmaceuticals Inc's cumulative twelve months Revenue were $ 9,869 millions, company would post below average annual Revenue growth of 2.65% year on year, if the fiscal year would end at Dec 31 2023. A slow-down in the Vertex Pharmaceuticals Inc's Revenue growth from the 2483.5% growth in Sep 30 2023.
Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 116, from total ranking in previous quarter at 345. |
Revenue TTM Q/Q Growth Statistics |
High |
Average |
Low |
147.95 % |
31.61 % |
-67.04 % |
|
|
|
|
|
Revenue TTM Y/Y Growth Statistics |
High |
Average |
Low |
147.95 % |
31.61 % |
-67.04 % |
|
|
|
Revenue TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 16 |
Sector |
# 38 |
S&P 500 |
# 399 |
|
Cumulative Revenue growth
Comment |
With the quarterly Revenue reported in the Dec 31 2023 period, Vertex Pharmaceuticals Inc's cumulative twelve months Revenue were $ 9,869 millions, company would post below average annual Revenue growth of -67.04% year on year, if the fiscal year would end at Dec 31 2023. A slow-down in the Vertex Pharmaceuticals Inc's Revenue growth from the 2483.5% growth in Sep 30 2023.
Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 116, from total ranking in previous quarter at 345. |
Revenue TTM Q/Q Growth Statistics |
High |
Average |
Low |
147.95 % |
31.61 % |
-67.04 % |
|
|
|
Revenue TTM Y/Y Growth Statistics |
High |
Average |
Low |
147.95 % |
31.61 % |
-67.04 % |
|
|
|
Revenue TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 16 |
Sector |
# 38 |
S&P 500 |
# 399 |
|